Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY22 results · Jan–Mar 2022
Sun Pharma Advanced Research Company reported revenue from operations of ₹25.24 crore (down 10.0% from Q4 FY21) and net loss of ₹71.05 crore for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 25.24 | 28.06 | −10.0% | 62.15 | −59.4% |
| Other income | 0.22 | 0.33 | −33.3% | 0.34 | −35.3% |
| Total income | 25.46 | 28.39 | −10.3% | 62.49 | −59.3% |
| Profit before tax | (71.05) | (56.72) | Loss widened | (15.84) | Loss widened |
| Net profit for the period | (71.05) | (56.72) | Loss widened | (15.84) | Loss widened |
| EPS, basic (₹) | (2.69) | (2.16) | Loss widened | (0.60) | Loss widened |
| Net margin (%) | -281.5 | -202.1 | -25.5 |
Standalone
- Filed with BSE
- 18 May 2022, 09:29 IST
- Board meeting
- 17 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE